Franklin Resources
FDMT icon

Franklin Resources’s 4D Molecular Therapeutics FDMT Stock Holding History

Franklin Resources’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-34,781
Closed -$314K – 2953
2024
Q3 		$314K Sell
34,781
-527
-1% -$8.75K ﹤0.01% 2473
2024
Q2 		$741K Buy
35,308
+8,471
+32% +$213K ﹤0.01% 2063
2024
Q1 		$855K Sell
26,837
-25,727
-49% -$656K ﹤0.01% 2014
2023
Q4 		$1.06M Buy
52,564
+38,202
+266% +$503K ﹤0.01% 1624
2023
Q3 		$183K Sell
14,362
-54
-0.4% -$903 ﹤0.01% 2342
2023
Q2 		$260K Buy
+14,416
New +$265K ﹤0.01% 2278

Other funds holding FDMT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Franklin Resources's FDMT Position: Q4 2024 in Review

Franklin Resources sold out of 4D Molecular Therapeutics (FDMT) in Q4 2024, closing a stake of 34,781 shares — an estimated $314K sold.

Franklin Resources first reported a position in FDMT in Q2 2023 and held it in 6 quarters. The position peaked at $1.06M in Q4 2023. 145 funds tracked by Wall St. Rank hold FDMT as of Q4 2024.

  • Franklin Resources reported no remaining 4D Molecular Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Franklin Resources sold 34,781 4D Molecular Therapeutics shares in Q4 2024, an estimated $314K.
  • Franklin Resources first reported a position in 4D Molecular Therapeutics in Q2 2023 and held it in 6 quarters.
  • Franklin Resources's 4D Molecular Therapeutics position peaked at $1.06M in Q4 2023.
  • 145 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2024.

Based on Franklin Resources's 13F filing for Q4 2024, filed 12 Feb 2025.